Novartis Ag (NVS) Operating Expenses (2009 - 2026)
Novartis Ag (NVS) posted Operating Expenses of $6.1 billion for Q2 2026, down 1.31% sequentially from $6.2 billion in Q2 2025, and down 1.31% YoY from $6.2 billion in Q2 2025.
Novartis Ag (NVS) Operating Expenses (2009 - 2026) Analysis & Trends
Novartis Ag has reported Operating Expenses for 18 years, with the latest figure at $6.1 billion in Q2 2026.
- Quarterly Operating Expenses fell 1.31% year-over-year to $6.1 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $6.1 billion (up 233.8% YoY) and the FY2025 annual result came in at $24.4 billion, up 8.23% from the prior year.
- Operating Expenses declined to $6.1 billion in Q2 2026 per NVS's latest filing, from $6.2 billion in the prior quarter.
- Over five years, Operating Expenses peaked at $6.2 billion in Q2 2025 and troughed at -$11.9 billion in Q4 2022.
- A 5-year average of -$3.7 billion and a median of -$5.4 billion in 2023 frame the typical range for Operating Expenses.
- The sharpest annual moves came in 2023 and 2025: Operating Expenses slipped 5.55% in 2023, then soared 213.03% in 2025.
- Over 5 years, Operating Expenses stood at -$11.9 billion in 2022, then rose by 8.82% to -$10.9 billion in 2023, then advanced by 1.31% to -$10.7 billion in 2024, then soared by 157.55% to $6.2 billion in 2025, then dropped by 1.31% to $6.1 billion in 2026.
- According to Business Quant data, Operating Expenses over the past three periods registered $6.1 billion, $6.2 billion, and -$10.7 billion for Q2 2026, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 10.12 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 10.56 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 12.80 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 6.09 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 9.70 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 6.54 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 18.20 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 6.68 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | -7.60 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | -5.98 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.09 Bn |
| Jun 30, 2025 | 6.17 Bn |
| Dec 31, 2024 | -10.72 Bn |
| Jun 30, 2024 | -5.46 Bn |
| Dec 31, 2023 | -10.86 Bn |
| Jun 30, 2023 | -5.40 Bn |
| Mar 31, 2023 | -761.00 Mn |
| Dec 31, 2022 | -11.91 Bn |
| Sep 30, 2022 | -672.00 Mn |
| Jun 30, 2022 | -6.08 Bn |
| Mar 31, 2022 | -721.00 Mn |
| Dec 31, 2021 | -12.03 Bn |
| Sep 30, 2021 | -704.00 Mn |
| Jun 30, 2021 | -6.15 Bn |
| Mar 31, 2021 | -716.00 Mn |
| Dec 31, 2020 | -11.36 Bn |
| Sep 30, 2020 | -704.00 Mn |
| Jun 30, 2020 | -5.81 Bn |
| Mar 31, 2020 | -714.00 Mn |
| Jun 30, 2019 | -5.64 Bn |